Industry Insights
-
Emerging Technologies In Aseptic Processing: Hype Vs. Operational Reality
6/8/2026
Let's debunk the misconception that robotics, gloveless systems, or fully closed isolators automatically result in Annex 1 compliance for cell and gene therapies.
-
Use Of AI In FDA Inspection Activities: Strategies For Effective Preparation
6/8/2026
Are you ready? FDA has begun to implement the use of artificial intelligence in its operations, particularly during inspection activities.
-
A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
6/5/2026
This is the first published application of data envelopment analysis to six major pharmaceutical analytical validation guidelines, including ICH Q2(R2), USP, ChP, and Brazil's ANVISA.
-
Inside AstraZeneca's Fully Electrified Cell Therapy Facility
6/5/2026
The company won an ISPE FOYA for its Rockville, Maryland, manufacturing site that boasts 100% uptime and flexible capacity to produce thousands of batches annually.
-
AI Has Arrived In Biotech CMC Amid Patchwork Governance
6/3/2026
AI is surfacing within regulatory and CMC workflows at a vigorous pace. Unfortunately, in small and midsize biotechs, it's happening faster than governance can keep up.
-
Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT
6/2/2026
Gene therapy’s next test is not proving it works, but proving it can scale.
-
CDMO Selection: Start With The Relationship, Not The RFP
6/1/2026
Friction often comes from unspoken expectations. Before production begins, treat the combined sponsor-CDMO group as one extended team and intentionally make “how we work together” visible.
-
Why FAT Should Confirm Alignment, Not Reveal Its Absence
6/1/2026
In many aseptic fill/finish projects, the factory acceptance test (FAT) has become the first true integration test of the entire project. That is a problem. Here's how to flip that mindset.
-
Managing Supply Disruptions In ATIMP Clinical Trials
6/1/2026
ATIMP trials leave little room for error. Learn how teams use contingency planning, real-time data, and AI to prevent supply disruptions.
- Why Cell And Gene Therapy Has Not Reached More Patients — And Why Clinical Operations Is The Bridge 5/29/2026